The European Network on Anti-Cancer Immuno-Therapy Improvement by modification of CAR and TCR Interactions and Nanoscale Geometry (EN-ACTI2NG), formed by 12 academic, clinical and industrial institutions from Spain, Austria, Germany, The Netherlands and the United Kingdom offers a multidisciplinary training for 10 early stage researchers in the development and analysis of engineered tumor-specific immune receptors. This network, funded by the H2020 Marie Sklodowska Curie Action program, emanates from recent clinical evidence that T cells expressing engineered tumor-specific immune receptors can eradicate tumors that do not respond to conventional treatment. This important therapeutic approach is in a very early phase of development and requires a well-trained workforce to address challenges such as development of tumor-specific receptors for a wider array of tumors, improvement in efficiency of these receptors, better on/off-target toxicity safety profiles and more efficient transfer of basic research findings to the clinic.

Application not later than May 1st 2017

Find out more